Abbott has introduced its line of next-generation systems, call Alinity, that span across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics.
Every platform within in the Alinity line includes features that will give institutions, clinicians and laboratorians an easier way to navigate the health care environment.
"Abbott's Alinity portfolio is unprecedented in the industry," Abbott’s EVP of Diagnostics Products Brian Blaser said. "With our unified family of testing instruments, we'll be able to offer more efficiency, flexibility and confidence to health systems and better help doctors and nurses get the results they need to improve decision-making and patient care."
Abbott’s research and development teams spoke with clinicians, scientists and technicians while developing Alinity.
"Abbott's Alinity systems are being built from the ground up based on customer insights, using the latest technologies suitable for testing today and in the future," Abbott’s VP of research and development of Diagnostics Products Dennis Gilbert said. "Whether it's an easy-to-use software interface, running more tests faster or the ability to run any test at any time, our Alinity platforms are designed to include these features and more without any compromise in performance or quality."